Evidence map›Paper›PMID 26020763›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2015

Adiponectin, Insulin Sensitivity and Diabetic Retinopathy in Latinos With Type 2 Diabetes.

Jane Z Kuo, Xiuqing Guo, Ronald Klein, Barbara E Klein, Pauline Genter, Kathryn Roll, Yang Hai, Mark O Goodarzi, Jerome I Rotter, Yii-Der Ida Chen and 1 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Mechanisms involved in the development of diabetic retinopathy induced by oxidative stress.Redox report : communications in free radical research · 2017
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jane Z KuoDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Xiuqing GuoDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Ronald KleinDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Barbara E KleinDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Pauline GenterDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Kathryn RollDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Yang HaiDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Mark O GoodarziDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Jerome I RotterDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Yii-Der Ida ChenDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Eli IppDepartment of Ophthalmology (J.Z.K.), Shiley Eye Center, UC San Diego, La Jolla, California 92093; Pathway Genomics Corporation (J.Z.K.), San Diego, California 92121; Institute for Translational Genomics and Population Sciences (X.G., K.R., Y.H., J.I.R., Y.-D.I.C.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Department of Ophthalmology and Visual Sciences (R.K., B.E.K.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726; Section of Diabetes and Metabolism (P.G., E.I.), Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502; Division of Endocrinology, Diabetes, and Metabolism (M.O.G.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
Harbor–UCLA Medical Center · USCedars-Sinai Medical Center · USFleet Science Center · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALAN R. SALTIEL · 2003 to 2026
$40.4M
Duke University Molecular Imaging CenterR24CA092656 · NCI · DUKE UNIVERSITY · PI JOHNSON, GEORGE ALLAN · 2001 to 2006
$3.7M
Small Animal Imaging Resource ProgramU24CA092656 · NCI · DUKE UNIVERSITY · PI JOHNSON, GEORGE ALLAN · 2007 to 2011
$2.2M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NCI NIH HHS R24 CA092656NCI NIH HHS U24 CA092656NIDDK NIH HHS P30 DK063491
6 · The paper itself

Abstract

CONTEXT AND

objectiveInsulin resistance and chronic inflammation are key elements in the pathogenesis of type 2 diabetes. We hypothesized that similar mechanisms could have a role in the development of diabetic retinopathy (DR), an important microvascular complication in Latinos with type 2 diabetes. DESIGN AND

settingA cross-sectional, family-based, observational cohort study. PATIENTS: Latino subjects with type 2 diabetes (n = 507), ascertained in families via a proband with known diabetes duration of 10 years or more and/or with DR, were included.

main outcome measuresSerum adiponectin was measured and insulin sensitivity was estimated using homeostasis model assessment of insulin resistance (HOMA-IR). DR was assessed by seven-field digital fundus photography and graded using the modified Airlie House classification and the Early Treatment Diabetic Retinopathy Scale (range of severity levels, 10-85).

resultsFasting adiponectin concentrations were elevated in patients with DR compared to those without (12.9 ± 0.5 vs 10.5 ± 0.5 μg/mL; P = .0004) and remained significant after adjusting for multiple covariates (age, gender, body mass index, glycosylated hemoglobin, diabetes duration, statin use, blood pressure, and renal function; P = .013 to .018). Adiponectin was also positively correlated with severity of DR in patients with nonproliferative DR (P < .0003), significant also after all covariate adjustments (P = .018). When the proliferative DR group was included, this relationship was attenuated by adjustments, possibly an influence of estimated glomerular filtration rate reduction in the proliferative DR group. HOMA-IR was not different in the DR and non-DR groups. Although elevated, adiponectin retained a typical inverse relationship with HOMA-IR in DR, similar to that seen in the non-DR group.

conclusionsSerum adiponectin is elevated in DR, is positively correlated with DR severity in Latinos with type 2 diabetes, and maintains a relationship to insulin sensitivity. Adiponectin, whether as a marker or biological mediator, may play an important role in DR, which appears to be independent of its relationship to insulin sensitivity.

Indexed as

AdiponectinBlood PressureBody Mass IndexCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic RetinopathyFemaleHispanic or LatinoHumansInsulinInsulin ResistanceMaleMiddle AgedRisk FactorsSeverity of Illness IndexAdiponectinInsulin

Identifiers

PMID26020763
PMCPMC4570164
OpenAlexW2177382145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.